Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
PCVX notice of proposed sale of 2,500 common shares via exercise of stock options on 03/11/2026. The filing lists shares outstanding of 143,920,361 as of 03/11/2026. It also records a prior sale of 11,623 shares on 12/23/2025 for $556,971.85.
PCVX filed a Form 144 notice to sell Common shares tied to RSU vestings. The filing lists multiple RSU vesting events and quantities, including 03/02/2026 — 1,803 shares; 02/28/2026 — 1,602 shares; 03/07/2026 — 1,740 shares; and 02/28/2025 — 2,250 shares. The entries are identified as RSU Vest and show the issuer as the source.
Vaxcyte, Inc. reported insider equity transactions by Elvia Cowan, its SVP, Finance & CAO. On February 26, 2026, Cowan received a grant of stock options for 17,855 shares and a separate award of 10,681 restricted stock units, each RSU representing one share of common stock.
The RSUs vest as to one quarter of the shares on September 7, 2026, then one eighth every six months, subject to continued service. The new option vests as to one forty-eighth of the shares on March 26, 2026, and monthly thereafter, also subject to continued service.
On the same date, Cowan exercised 7,716 stock options at $25.92 per share, receiving the same number of common shares. On February 28 and March 2, 2026, a total of 569 shares were surrendered at $61.98 per share to cover tax withholding on vested RSUs. After these transactions, Cowan directly owned 31,362 common shares.
Vaxcyte, Inc. reported that President and CFO Andrew Guggenhime received equity awards and had shares withheld to cover taxes. On February 26, 2026, he was granted 44,864 shares of common stock in the form of RSUs and 74,993 stock options. On February 28 and March 2, 2026, a total of 1,907 shares of common stock were surrendered to the company to satisfy tax withholding on RSU vesting. He also reports indirect ownership of 61,850 shares held by ALG 2025 GRAT HOLDINGS LLC, a grantor retained annuity trust for which he is annuitant and trustee.
Vaxcyte, Inc. director and chief executive officer Grant Pickering reported equity compensation grants and related tax-withholding share dispositions. On February 26, 2026, he received a grant of 105,110 shares of Common Stock and a stock option for 175,698 shares, both at a stated price of $0.00 per share, as awards. The option vests as to 1/48 of the shares on March 26, 2026, then 1/48 monthly thereafter, subject to continued service. The common stock award represents RSUs that vest 1/4 on September 7, 2026 and 1/8 every six months after, also contingent on continued service. To cover tax withholding from RSU vesting, he surrendered 2,531 shares on March 2, 2026 and 2,863 shares on February 28, 2026 at $61.98 per share. After these transactions, he directly owned just over 500,000 Common Stock shares, with additional indirect holdings reported through trusts for the benefit of his son and daughter.
Vaxcyte, Inc. reported insider equity activity by Chief Technical Ops Officer Harpreet S. Dhaliwal. On February 26, 2026, Dhaliwal received grants of 53,409 shares of common stock and 46,424 stock options, both at a reported price of $0.00 per share as awards. The common stock grant represents restricted stock units that vest over time starting September 7, 2026. On February 28 and March 2, 2026, a total of 757 shares of common stock were disposed of at $61.98 per share to cover tax withholding obligations upon RSU vesting. After these transactions, Dhaliwal directly held 76,580 shares of common stock.
Vaxcyte, Inc. chief operating officer Jim Wassil reported equity compensation activity and related tax withholdings. He received 32,045 restricted stock units at a grant price of $0.00 per share, plus an additional 5,102 RSUs at $61.74 per share. He was also granted a stock option for 53,566 shares at a $0.00 exercise price, vesting in monthly installments beginning March 26, 2026.
To cover tax obligations from RSU vesting, shares of common stock were surrendered back to the company: 1,900 shares at $61.74 per share, 898 shares at $61.98 per share, and 1,009 shares at $61.98 per share. After these transactions, he directly owned 175,188 shares of common stock.
Vaxcyte, Inc. entered a new at-the-market stock offering program allowing it to sell up to $500,000,000 of common stock through Leerink Partners as placement agent under an existing shelf registration on Form S-3.
The shares may be sold from time to time on Nasdaq or other permitted markets, with Leerink Partners earning up to 3.00% of gross proceeds. Vaxcyte simultaneously terminated its prior Open Market Sale Agreement with Jefferies, under which it had previously sold approximately $270.3 million of common stock.
Vaxcyte entered into a sales agreement on February 24, 2026 to sell up to $500.0 million of its common stock in an at-the-market offering through Leerink Partners LLC.
The sales agent may sell shares from time to time on mutually agreed terms and will receive a commission of up to 3.0% of gross proceeds. The prospectus cites the last reported sale price of $60.26 per share on February 23, 2026 and states 131,058,858 shares outstanding as of December 31, 2025. The supplement illustrates an example sale of 8,297,378 shares at $60.26 for aggregate gross proceeds of approximately $500.0 million, and shows dilution to new investors of $38.34 per share in that example.
Vaxcyte, Inc. is a clinical-stage vaccine company using its XpressCF cell-free protein synthesis platform to engineer high-fidelity vaccines against serious bacterial diseases. The company focuses on broad-spectrum pneumococcal conjugate vaccines (PCVs) and other novel conjugate and protein vaccines for adults and children.
Its lead candidate, VAX-31, is a 31-valent, carrier-sparing PCV designed to cover about 95% of invasive pneumococcal disease (IPD) in U.S. adults 50+ and about 92% of IPD in children under five. VAX-31 showed strong safety and immunogenicity in a 1,015‑patient Phase 1/2 adult trial versus PCV20, leading to selection of the high dose for a Phase 3 program. The FDA granted breakthrough therapy designation for adult IPD and later expanded it to pneumonia, and Vaxcyte has started three Phase 3 adult studies (OPUS‑1, OPUS‑2 and OPUS‑3).
In pediatrics, VAX-31 is in a large Phase 2 infant dose‑finding study using an optimized higher-dose arm, with enrollment completed and topline data expected in the first half of 2027. VAX-24, a 24‑valent PCV, delivered positive Phase 2 results in infants, showing robust IgG and OPA responses and little evidence of carrier suppression. Additional programs include VAX-A1 for Group A Streptococcus, planned to enter Phase 1 in 2026, and VAX-GI for Shigella, which is paused beyond preclinical work as resources are prioritized toward the PCV franchise.